GE Healthcare has highlighted an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine (SNM). One example of how GE Healthcare has improved clinician’s experience for patients is through dose management. Another example of GE Healthcare’s commitment to responsible dose management is the ability to reduce injected dose by up to 50 percent compared with standard cardiac and bone protocols.

Read the full story here

Cleveland BioLabs, Inc. announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS). CBLB502 is being developed by Cleveland BioLabs under the FDA’s Animal Efficacy Rule to treat Acute Radiation Syndrome (ARS) or radiation poisoning from any exposure to radiation such as a nuclear or radiological weapon / dirty bomb, or from a nuclear accident.

For the full story, Click Here